Journal of Molecular Science

Journal of Molecular Science
Volume 33 Issue 2, Year of Publication 2023, Page 25-27
DoI-17.4687/1000-9035.2023.010

Journal of Molecular Science
www.jmolecularsci.com ISSN:1000-9035

Epigenetic Regulation of Oncogenes and Tumor Suppressor Genes: Mechanistic Insights into DNA Methylation and Histone Modifications in Cancer Pathogenesis

Thomas Daniel Jenkins, Amelia Rose Phillips, Edward John Morgan, Clara May Bailey, Leo Thomas Harrison

Article Information
Received: 25-04-2023
Revised: 10-05-2023
Accepted: 19-05-2023
Published: 19-06-2025

Keywords
Cancer Pathogenesis

ABSTRACT
Cancer development is intricately linked to epigenetic dysregulation, particularly through alterations in DNA methylation and histone modifications. These epigenetic modifications influence gene expression without altering the DNA sequence, thereby modulating the activity of oncogenes and tumor suppressor genes. This review delves into the mechanistic aspects of epigenetic modifications in cancer, emphasizing their roles in gene silencing, chromatin remodeling, and transcriptional regulation. We also explore the therapeutic potential of epigenetic drugs targeting aberrant methylation and histone modifications. Understanding these mechanisms provides insights into novel cancer diagnostics and treatment strategies.

INTRODUCTION:

Epigenetics encompasses heritable modifications in gene expression that do not alter the DNA sequence but significantly impact cellular function and disease progression. Unlike genetic mutations, epigenetic changes are reversible and influenced by environmental factors, lifestyle, and aging. Two key epigenetic mechanisms implicated in carcinogenesis are DNA methylation and histone modifications. DNA methylation, primarily occurring at CpG islands, typically represses gene expression, while histone modifications, such as acetylation and methylation, can either activate or silence transcription depending on their specific context. Dysregulation of these processes can lead to abnormal oncogene activation or tumor suppressor gene silencing, driving tumor initiation and progression. Understanding these mechanisms has paved the way for epigenetic therapies, including DNA methyltransferase inhibitors and histone deacetylase inhibitors, which aim to restore normal gene expression patterns. Future research should focus on refining these therapeutic strategies and exploring novel epigenetic targets for precision oncology.

2. DNA Methylation and Cancer

DNA methylation occurs primarily at cytosine

Journal of Molecular Science
Volume 33 Issue 2, Year of Publication 2023, Page 25-27
DoI-17.4687/1000-9035.2023.010

residues in CpG dinucleotides, mediated by DNA methyltransferases (DNMTs). Hypermethylation of tumor suppressor gene promoters is a common epigenetic alteration in cancer, leading to gene silencing. Conversely, global hypomethylation can activate oncogenes and promote genomic instability.

2.1 Hypermethylation of Tumor Suppressor Genes

Promoter hypermethylation is a hallmark of many cancers, affecting genes such as **p16INK4a, BRCA1, and MLH1**. This silencing leads to disrupted cell cycle control, DNA repair deficiencies, and apoptotic resistance. Studies indicate that hypermethylation of MLH1 is a key event in microsatellite instability-positive colorectal cancers (Jones & Baylin, 2007).

2.2 Hypomethylation and Oncogene Activation

Global DNA hypomethylation can lead to oncogene activation, chromosomal instability, and increased mutation rates. Hypomethylation of **MYC** and **Ras** oncogenes has been observed in various malignancies, contributing to uncontrolled cell proliferation (Robertson et al., 2011).

Table 1: DNA Methylation Patterns in Cancer

Gene	Type of Methylation	Cancer Type	Consequence
p16INK4a	Hypermethylation	Lung, Breast	Loss of cell cycle control
BRCA1	Hypermethylation	Breast, Ovarian	Defective DNA repair
MYC	Hypomethylation	Colorectal, Liver	Oncogene activation
Ras	Hypomethylation	Pancreatic, Thyroid	Increased proliferation

3. Histone Modifications and Their Role in Tumorigenesis

Histone proteins undergo post-translational modifications such as methylation, acetylation, phosphorylation, and ubiquitination, which regulate chromatin structure and gene expression. These modifications are mediated by enzymes like histone acetyltransferases (HATs), histone deacetylases (HDACs), histone methyltransferases (HMTs), and demethylases (HDMs).

3.1 Histone Acetylation and Deacetylation

Histone acetylation, catalyzed by HATs, is associated with active gene transcription, while deacetylation by HDACs leads to chromatin condensation and gene silencing. Overexpression of HDACs has been observed in various cancers, contributing to tumorigenesis by repressing tumor suppressor genes (Singh et al., 2020).

3.2 Histone Methylation and Cancer



Fig.Histone Methylation

Histone methylation can have activating or repressive effects depending on the specific lysine residues modified. For instance, **H3K27me3**, mediated by EZH2, is linked to transcriptional repression of tumor suppressor genes in prostate and breast cancer (Cao et al., 2002).

Table 2: Histone Modifications in Cancer

Histone Mark	Enzyme	Cancer Type	Effect
H3K27me3	EZH2	Breast, Prostate	Gene repression
H3K9ac	HATs	Leukemia, Colon	Gene activation
H4K16ac	HATs	Liver, Pancreatic	Gene activation
H3K9me3	SUV39H1	Glioblastoma	Gene silencing

4. Epigenetic Therapy: Potential and Challenges



Fig.Epigenetic Therapy

Given the reversible nature of epigenetic modifications, epigenetic therapies have emerged as promising strategies in cancer treatment. DNA methylation inhibitors such as **5-azacytidine** and HDAC inhibitors like **vorinostat** have shown efficacy in hematological malignancies and solid tumors. However, challenges such as off-target effects and acquired resistance limit their widespread application (Arrowsmith et al., 2012).

5. CONCLUSION

Epigenetic modifications, particularly DNA methylation and histone modifications, play a

Journal of Molecular Science
Volume 33 Issue 2, Year of Publication 2023, Page 25-27
DoI-17.4687/1000-9035.2023.010

crucial role in cancer progression by regulating oncogenes and tumor suppressor genes. Understanding these mechanisms provides valuable insights into novel therapeutic approaches. Future research should focus on refining epigenetic drugs to enhance specificity and minimize adverse effects.

REFERENCES:

1. Jones PA, Baylin SB. (2007). The epigenomics of cancer. *Cell*, 128(4), 683-692.
2. Robertson KD, et al. (2011). DNA methylation and human disease. *Nature Reviews Genetics*, 12(7), 529-541.
3. Singh N, et al. (2020). Histone modifications in cancer epigenetics. *Clinical Epigenetics*, 12(1), 20.
4. Cao R, et al. (2002). Role of histone methylation in polycomb-group gene silencing. *Science*, 298(5595), 1039-1043.
5. Arrowsmith CH, et al. (2012). Epigenetic protein families: A new frontier for drug discovery. *Nature Reviews Drug Discovery*, 11(5), 384-400.